Clinical Trial Update: Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Ankylosing Spondylitis | Phase 3 | Status: COMPLETED | Results posted: 2019-09-09